Given that GRI treatment significantly reduces circulatory RBC numbers, our results suggest the potential application of LPA2 agonists on several myeloproliferative diseases, including thrombocythemia, polycythemia vera, and primary myelofibrosis41. The gene discussed is LPAR2; the disease is myeloproliferative disorder.